Karyopharm Therapeutics
Stock Forecast, Prediction & Price Target
Karyopharm Therapeutics Financial Estimates
Karyopharm Therapeutics Revenue Estimates
Karyopharm Therapeutics EBITDA Estimates
Karyopharm Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $209.81M N/A | $157.07M -25.13% | $146.03M -7.02% | Avg: $165.02M Low: $126.59M High: $198.28M avg. 13.00% | Avg: $233.56M Low: $202.27M High: $266.45M avg. 41.53% | Avg: $321.20M Low: $278.17M High: $366.43M avg. 37.52% | Avg: $328.96M Low: $284.89M High: $375.28M avg. 2.41% |
Net Income
% change YoY
| $-124.08M N/A | $-165.29M -33.20% | $-143.09M 13.42% | Avg: $-145.35M Low: $-134.78M High: $-65.10M avg. -1.57% | Avg: $-113.05M Low: $-70.81M High: $-62.82M avg. 22.22% | Avg: $-13.13M Low: $-15.53M High: $-10.84M avg. 88.38% | Avg: $-10.27M Low: $-12.16M High: $-8.48M avg. 21.73% |
EBITDA
% change YoY
| $-97.77M N/A | $-139.92M -43.11% | $-118.42M 15.36% | Avg: $-139.94M Low: $-168.15M High: $-107.36M avg. -18.17% | Avg: $-198.07M Low: $-225.96M High: $-171.53M avg. -41.53% | Avg: $-272.40M Low: $-310.75M High: $-235.90M avg. -37.52% | Avg: $-278.98M Low: $-318.26M High: $-241.60M avg. -2.41% |
EPS
% change YoY
| -$1.65 N/A | -$2.02 -22.42% | -$1.25 38.11% | Avg: -$0.83 Low: -$1.18 High: -$0.57 avg. 33.4% | Avg: -$0.58 Low: -$0.62 High: -$0.55 avg. 30.33% | Avg: -$0.12 Low: -$0.14 High: -$0.09 avg. 80.17% | Avg: -$0.09 Low: -$0.11 High: -$0.07 avg. 21.73% |
Operating Expenses
% change YoY
| $304.68M N/A | $294.06M -3.48% | $270.63M -7.96% | Avg: $206.66M Low: $158.54M High: $248.32M avg. -23.63% | Avg: $292.51M Low: $253.32M High: $333.70M avg. 41.53% | Avg: $402.27M Low: $348.38M High: $458.92M avg. 37.52% | Avg: $411.99M Low: $356.79M High: $470.00M avg. 2.41% |
FAQ
What is Karyopharm Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 32.69% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -134.78M, average is -145.35M and high is -65.10M.
What is Karyopharm Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 23.61% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $126.59M, average is $165.02M and high is $198.28M.
What is Karyopharm Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 41.41% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.18, average is -$0.83 and high is $-0.57.
What is the best performing analyst?
In the last twelve months analysts have been covering Karyopharm Therapeutics stock. The most successful analyst is Collen Kusy.